**Question:** All of the following are GpIIb/IIIa antagonist, except:

A. Abciximab
B. Eptifibatide
C. Argatroban
D. Heparin

**Core Concept:** GpIIb/IIIa antagonists are a class of medications that inhibit platelet aggregation, thereby preventing blood clot formation and dissolving pre-existing clots. GpIIb/IIIa receptors are found on the surface of activated platelets and play a key role in the process of platelet aggregation and fibrin clot formation.

**Why the Correct Answer is Right:** Heparin is a well-known anticoagulant, not a direct inhibitor of platelet aggregation. While it can indirectly inhibit platelet aggregation by preventing the activation of factor Xa and thrombin, it does not target GpIIb/IIIa receptors directly.

**Why Each Wrong Option is Incorrect:**

A. Abciximab: Abciximab is a monoclonal antibody that specifically binds to the GpIIb/IIIa receptor, preventing its activation and thus inhibiting platelet aggregation. It is a direct GpIIb/IIIa antagonist.

B. Eptifibatide: Eptifibatide is a cyclic peptide that also specifically binds to the GpIIb/IIIa receptor, preventing its activation and inhibiting platelet aggregation. It is also a direct GpIIb/IIIa antagonist.

C. Argatroban: Argatroban is a direct thrombin inhibitor, which blocks the activation of factor Xa and prevents the formation of fibrin clots. It does not target the GpIIb/IIIa receptor and is not a GpIIb/IIIa antagonist.

**Clinical Pearl:** In clinical practice, GpIIb/IIIa antagonists like abciximab and eptifibatide are commonly used to prevent and treat acute coronary syndromes, particularly in patients undergoing percutaneous coronary intervention (PCI). They are crucial in preventing platelet aggregation and reducing the risk of thrombotic complications during and after PCI procedures.